Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab for refractory or relapsed idiopathic thrombocytopaenic purpura
ACTRN12612000591853Phase 2Recruiting
- Sponsor
- Florence Peterson Fund
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in immune thrombocytopenia (ITP), sponsored by Florence Peterson Fund. Primary endpoint: Overall response rate. Started Dec 2009; status: recruiting.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ACTRN12612000591853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000591853.